News Big pharma could turn to viruses to boost cancer immunothera... Norwegian biotech looking for development partners
News Immunotherapy arms race latest: Merck buys Viralytics for $3... Big pharma pays 160% premium for Australian biotech
News US judge overturns Gilead $2.54bn patent infringement ruling Federal judge throws out Merck's patent claim against Gilead
News Concerns mount over Biogen Alzheimer's drug FDA announces guidance to encourage development of new drugs
News BMS makes record $1.8bn bet on Nektar cancer drug Bristol-Myers Squibb scored a first-in-class approval with cancer immunotherapy Opdivo just a few years ago – could it be about repeat the trick with a new drug that stimulates natural kill
News Doubts over BACE drugs after Merck ends Alzheimer's trial Decision comes a year after Merck axed EPOCH verubecestat trial
Digital On AI and computational support of biochemistry, with Alan R... Dr Alan Roth, CEO of Oxford Drug Design, discusses the use of AI to accelerate discovery of new treatments.
Sales & Marketing Sponsored The AI imperative: Establishing the standard for modern clin... The findings from the Medidata-commissioned survey confirm that AI implementation in clinical trials has moved firmly beyond theoretical discussion.
